Tauriga Sciences Inc. Appoints Electrofluidics Expert Jason C. Heikenfeld Ph.D as a Member of the Company's Scientific Adviso...
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the appointment of Jason C. Heikenfeld Ph.D ("Dr. Heikenfeld") as the third member of company's scientific advisory board. Dr. Heikenfeld currently serves as Director of the Novel Devices Laboratory ("NDL") at the University of Cincinnati, where he is an internationally known expert in the fields of electrofluidics and flex-electronics. His main objectives will be to assist the company in conducting important laboratory work and the designing of an industry specific Bacterial Robot ("BactoBot") prototype for the nuclear power industry.
Commenting on his appointment, Dr. Heikenfeld stated, "The University of Cincinnati is excited to participate in Tauriga's effort, bringing to the project world-class rapid-prototyping and engineering of fluidic devices within the Ohio Center of Microfluidic Innovation and the Novel Devices Laboratory. This is a perfect confluence of the right factors: enormous un-met market opportunity, solid business strategy, and now, full access for Tauriga to the multidisciplinary talent required for technology development."
Tauriga's CEO Seth M. Shaw commented, "The company is pleased to have Dr. Heikenfeld join its scientific advisory board as his knowledge base and world class experience are important assets to the Company moving forward. We look forward to working with the University of Cincinnati's prestigious laboratories in developing a new technology platform capable of benefiting both industry and society."
Personal BIO for Jason C. Heikenfeld, Ph.D., age 39
Dr. Jason Heikenfeld is an internationally-known expert in electrofluidics and flex-electronics, with work spanning displays, lab-on-chip, and now wearable sensors. Dr. Heikenfeld is a recipient of NSF CAREER, and AFOSR and Sigma Xi Young-Investigator awards. He is currently a Prof. of Electrical Engineering at the University of Cincinnati and also currently working with his second start-up company in color-video electronic paper. Dr. Heikenfeld is a Senior member of the Institute for Electrical and Electronics Engineers, a Senior member of the Society for Information Display, and a member of SPIE. Website: (www.ece.uc.edu/devices) Google Scholar Profile: (http://scholar.google.com/citations)
Jason Heikenfeld received his B.S. and Ph.D. degrees from the University of Cincinnati in 1998 and 2001, respectively. During 2001-2005 Dr. Heikenfeld co-founded and served as principal scientist at Extreme Photonix Corp. In 2005 he returned to the University of Cincinnati as a Professor in the Dept. of Electrical & Computer Engineering.
In 2005, Dr. Heikenfeld joined the University of Cincinnati ("UC") as an Assistant Professor, and quickly propelled UC into a position of international leadership in electrofluidic technology. Dr. Heikenfeld's university laboratory, The Novel Devices Laboratory www.ece.uc.edu/devices, is currently engaged in electrofluidic device research spanning electronic paper and biomedical applications. Since 2006, he has secured more than $12,000,000 in funded research, including a prestigious NSF CAREER award and a AFOSR Young Investigator Award (one of only 21 nationally in 2006, across all sciences). He has greater than 150 publications and his inventions have resulted in over 10 granted patents. Dr. Heikenfeld has now launched his second company, Gamma Dynamics, which is pursuing commercialization of color e-Readers that look as good as conventional printed media. Dr. Heikenfeld is a Senior member of the Institute for Electrical and Electronics Engineers, a Senior member of the Society for Information Display, and a member of SPIE. In addition to his scholarly work, Dr. Heikenfeld is an award winning educator at UC and has lead the creation of programs and coursework at the University of Cincinnati that foster innovation, entrepreneurship, and an understanding of the profound change that technology can have on society.
Tauriga Sciences, Inc. no longer focuses its efforts exclusively in the biotechnology space, so the previously designated medical advisory board has been changed to the scientific advisory board to better reflect to the new direction of the business.
On October 29, 2013 Tauriga announced a comprehensive Strategic Alliance with Cincinnati, Ohio-based Bacterial Robotics LLC and its wastewater-to-value subsidiary, Pilus Energy. The Agreement stipulates the formation of a Joint Venture Partnership ("JVP") for the development and commercialization of a nuclear power industry specific Bacterial Robot, or BactoBot(TM).
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.tauriga.com.
About Novel Devices Laboratory ("NDL") at the University of Cincinnati
NDL performs highly multidisciplinary research, primarily in electrofluidics and biosensors, spanning fundamental science to more applied work through industrial partnerships (see our Research page). Furthermore, NDL has the practical knowledge, facilities, and a strong track-record for rapidly transforming novel concepts into commercially viable prototypes. Since 2006, NDL has partnered with numerous U.S., European, and Asian companies in pushing new technologies to market (click here for support map). NDL is also a founding member of the NSF Center for Advanced Design and Manufacturing of Integrated Microfluidics (CADMIM), lead founder for the Ohio Center for Microfluidic Innovation (OCMI), and founding member of the Nano-Bio Manufacturing Consortium (NBMC). Please visit the website at (http://www.ece.uc.edu/devices/).
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
CONTACT: For further information regarding
Tauriga Sciences, Inc.:
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the appointment of Jason C. Heikenfeld Ph.D ("Dr. Heikenfeld") as the third member of company's scientific advisory board. Dr. Heikenfeld currently serves as Director of the Novel Devices Laboratory ("NDL") at the University of Cincinnati, where he is an internationally known expert in the fields of electrofluidics and flex-electronics. His main objectives will be to assist the company in conducting important laboratory work and the designing of an industry specific Bacterial Robot ("BactoBot") prototype for the nuclear power industry.
Commenting on his appointment, Dr. Heikenfeld stated, "The University of Cincinnati is excited to participate in Tauriga's effort, bringing to the project world-class rapid-prototyping and engineering of fluidic devices within the Ohio Center of Microfluidic Innovation and the Novel Devices Laboratory. This is a perfect confluence of the right factors: enormous un-met market opportunity, solid business strategy, and now, full access for Tauriga to the multidisciplinary talent required for technology development."
Tauriga's CEO Seth M. Shaw commented, "The company is pleased to have Dr. Heikenfeld join its scientific advisory board as his knowledge base and world class experience are important assets to the Company moving forward. We look forward to working with the University of Cincinnati's prestigious laboratories in developing a new technology platform capable of benefiting both industry and society."
Personal BIO for Jason C. Heikenfeld, Ph.D., age 39
Dr. Jason Heikenfeld is an internationally-known expert in electrofluidics and flex-electronics, with work spanning displays, lab-on-chip, and now wearable sensors. Dr. Heikenfeld is a recipient of NSF CAREER, and AFOSR and Sigma Xi Young-Investigator awards. He is currently a Prof. of Electrical Engineering at the University of Cincinnati and also currently working with his second start-up company in color-video electronic paper. Dr. Heikenfeld is a Senior member of the Institute for Electrical and Electronics Engineers, a Senior member of the Society for Information Display, and a member of SPIE. Website: (www.ece.uc.edu/devices) Google Scholar Profile: (http://scholar.google.com/citations)
Jason Heikenfeld received his B.S. and Ph.D. degrees from the University of Cincinnati in 1998 and 2001, respectively. During 2001-2005 Dr. Heikenfeld co-founded and served as principal scientist at Extreme Photonix Corp. In 2005 he returned to the University of Cincinnati as a Professor in the Dept. of Electrical & Computer Engineering.
In 2005, Dr. Heikenfeld joined the University of Cincinnati ("UC") as an Assistant Professor, and quickly propelled UC into a position of international leadership in electrofluidic technology. Dr. Heikenfeld's university laboratory, The Novel Devices Laboratory www.ece.uc.edu/devices, is currently engaged in electrofluidic device research spanning electronic paper and biomedical applications. Since 2006, he has secured more than $12,000,000 in funded research, including a prestigious NSF CAREER award and a AFOSR Young Investigator Award (one of only 21 nationally in 2006, across all sciences). He has greater than 150 publications and his inventions have resulted in over 10 granted patents. Dr. Heikenfeld has now launched his second company, Gamma Dynamics, which is pursuing commercialization of color e-Readers that look as good as conventional printed media. Dr. Heikenfeld is a Senior member of the Institute for Electrical and Electronics Engineers, a Senior member of the Society for Information Display, and a member of SPIE. In addition to his scholarly work, Dr. Heikenfeld is an award winning educator at UC and has lead the creation of programs and coursework at the University of Cincinnati that foster innovation, entrepreneurship, and an understanding of the profound change that technology can have on society.
Tauriga Sciences, Inc. no longer focuses its efforts exclusively in the biotechnology space, so the previously designated medical advisory board has been changed to the scientific advisory board to better reflect to the new direction of the business.
On October 29, 2013 Tauriga announced a comprehensive Strategic Alliance with Cincinnati, Ohio-based Bacterial Robotics LLC and its wastewater-to-value subsidiary, Pilus Energy. The Agreement stipulates the formation of a Joint Venture Partnership ("JVP") for the development and commercialization of a nuclear power industry specific Bacterial Robot, or BactoBot(TM).
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.tauriga.com.
About Novel Devices Laboratory ("NDL") at the University of Cincinnati
NDL performs highly multidisciplinary research, primarily in electrofluidics and biosensors, spanning fundamental science to more applied work through industrial partnerships (see our Research page). Furthermore, NDL has the practical knowledge, facilities, and a strong track-record for rapidly transforming novel concepts into commercially viable prototypes. Since 2006, NDL has partnered with numerous U.S., European, and Asian companies in pushing new technologies to market (click here for support map). NDL is also a founding member of the NSF Center for Advanced Design and Manufacturing of Integrated Microfluidics (CADMIM), lead founder for the Ohio Center for Microfluidic Innovation (OCMI), and founding member of the Nano-Bio Manufacturing Consortium (NBMC). Please visit the website at (http://www.ece.uc.edu/devices/).
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
CONTACT: For further information regarding
Tauriga Sciences, Inc.:
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com
